

Investor Update

Dr Jeremy Levin, Executive Chairman

17 December 2025



Important notice and disclaimer

This presentation has been prepared by Opthea Limited (ABN 32 006 340 567) ("Opthea" or "Company") to provide summary information about Opthea and its affiliates and subsidiaries (the "Opthea Group") and their activities. The information contained in this presentation is of general background, does not purport to be complete, is provided as at the date of this presentation and remains subject to change without notice. Except as otherwise required by law, Opthea has no obligation to update or correct this presentation. This presentation should be read in conjunction with Opthea's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange ("ASX"), which are available at www.asx.com.au.

The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) for investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. Nothing in this presentation constitutes or forms part of any offer, invitation, solicitation or recommendation to buy or sell securities.

All references to dollar amounts are references to Australian dollars ("A\$" or "\$") unless otherwise stated. This presentation is unaudited.

This presentation contains certain forward-looking statements. Forward looking statements can generally be identified by the use of words such as "project", "foresee", "forecast", "plan", "expect", "aim", "ambition", "aspiration", "potential", "goal", "objective", "target", "intend", "see", "anticipate", "expect", "believe", "trend", "estimate", "may", "could", "should", "would", "need", "will", "must", "commit", "guidance" or similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements may also be made, verbally or in writing, by members of Opthea Group's management or Opthea's board in connection with this presentation. Such statements are subject to the same limitations, uncertainties, assumptions and disclaimers set out in this presentation. Forward looking statements, opinions, and estimates provided in this presentation involve a number of risks, assumptions and contingencies, many of which are beyond Opthea's control and which are subject to change without notice. It is believed that the expectations reflected in these forward-looking statements, opinions and estimates are reasonable at this time, but there can be no assurance that actual outcomes will not differ materially from these statements. Such forward looking statements, opinions and estimates are provided as a general guide only, should not be relied on as an indication or guarantee of future performance. You should not place undue reliance on forward looking statements. An investment in Opthea securities is subject to investment and other known and unknown risks, some of which are beyond the control of the Opthea Group including risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Opthea Annual Report. Opthea does not guarantee any particular rate of return or the performance of the Opthea Group nor does it guarantee the repayment of capital from Opthea or any particular tax treatment.

This presentation may include statistical and other industry and market data obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Such data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities include several key assumptions based on our industry knowledge, industry publications, third party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

No representation or warranty, express or implied, is made as to the accuracy, completeness or reliability of the information. To the fullest extent permitted by law, neither Opthea nor any other member of the Opthea Group nor any of their or its directors, officers, employees and advisers accept any liability for any loss arising from reliance on this presentation or its contents.

This presentation may contain trademarks and other trade names of third parties, which are the property of their respective owners. Third party trademarks and trade names used in this presentation belong to the relevant owners and use is not intended to represent sponsorship, approval or association by or with any of the Opthea Group.

Our intention:

Opthea is relaunching, using all the assets and knowledge we have in VEGF-C/D, to target Lymphangioliomyomatosis (LAM) – a rare disorder with major unmet medical need, which fits the biology of OPT-302



Agenda

CURRENT STATUS

STRATEGIC REVIEW

OUTCOME OF REVIEW

WHY LYMPHANGIOLEIOMYOMATOSIS (LAM)

REINSTATEMENT OF QUOTATION ON ASX

CONCLUSION AND Q&A

Current status:

Strong IP, experienced team and cash reserves

OPTHEA

Drug development

Local operations

Local ASX listing

Global outlook

STRONG IP

Patents

- Global portfolio of IP that could extend protection to 2046

OPT-302 package

- Registration ready-data
- Manufacturing data
- Non-clinical and clinical package
- Known safety profile

AN EXPERIENCED TEAM

Board

- Jeremy Levin (Chair)
- Kathy Connell
- Lawrence Gozlan
- Hamish George (Joint CoSec)
- Stephanie Vipond (Joint CoSec)

Management

- Jeremy Levin (Exec Chair)
- Stuart Mudge (COO)
- Mike Gerometta (CTO)¹
- Hamish George (CFO)

CASH RESERVES

Cash

- A\$37.6m²
- Significant runway

Tax credit

- A\$10.8m R&D Tax incentive received

Fiscal discipline

- Committed to disciplined capital management and transparent investor communication

A disciplined strategic review:

Prioritised feasibility, shareholder value and ROI


The Board explored several strategic and value creating options for Opthea and the underlying shareholder capital

OPTION	RETURN OF CAPITAL	ACQUISITION OF ASSETS OR MERGER	REPURPOSE OPT-302 ASSETS AND EVALUATE OTHER VEGF ASSETS
ASSESSMENT	<ul style="list-style-type: none"> ✗ Minimal ROI ✗ IP written off ✗ Value leaking ✗ Upside forfeited ✓ Execution 	<ul style="list-style-type: none"> — Medium ROI ✗ Long lead time ✗ Asset risk ✗ Shareholder dilution — Execution 	<ul style="list-style-type: none"> ✓ ROI potential if successful ✓ Shorter lead times ✓ Asset well understood ✓ No near-term shareholder dilution ✓ Ability to leverage existing body of data towards another disease mediated by VEGF C/D

Outcome of review:


Targeting high need indications for Opthea's portfolio with path to commercial viability

Identifying the most promising re-purposing of OPT-302



About LAM:

A rare disease with significant unmet needs affecting young women



3-8 women in every one million worldwide^{1, 2}

Genetic condition

Not caused by lifestyle choices

35

Average age of diagnosis

- Abnormal smooth-muscle-like cells (“LAM”) cells infiltrate lungs and lymph channels
- LAM cells overproduce VEGF-C and VEGF-D, driving abnormal lymphatics and fluid problems²
- Multiple cysts form throughout the lung³, trapping air, destroying tissue and creating air leaks
- Over time this leads to a steady loss of breathing capacity, incapacitation and reduced lifespan
- mTOR inhibitors can stabilise disease on treatment, but do not cure LAM and progression often returns off therapy
- Patients may face progressive lung loss and lymphatic complications, with tolerability limits. Creating the need for an add-on biologic targeting complementary biology

No existing cure

1. Prevalence is reported as 3.4-7.8 cases per million women but newer Northern Europe data suggest 20.9-26.04 per million adult women, consistent with underdiagnosis.

2. Issaka, R. B., et al. (2009). See Appendix for full citation.

3. LAM can also be present elsewhere in the body including the kidneys for 40% of women with LAM. **Source:** [Living with LAM](#).

LAM market and commercial logic:

Concentrated rare-disease pathway with limited disease-modifying therapy




Prevalence reported as 3.4–7.8 cases per million adult women; but newer data suggests **20.9–26.04 per million**, consistent with underdiagnosis¹



Patients are concentrated and managed by a **finite specialty footprint**, with ~70 global LAM clinics³



Current disease-modifying therapy is **not curative**: in the pivotal randomised trial², sirolimus stabilised lung function on treatment, but decline resumed after discontinuation



Standardised patient identification for a rare lung disease: ATS/JRS guidelines recommend using serum VEGF-D with an 800 pg/mL threshold to support




Commercial reality: orphan-drug **pricing spans a wide, well-established range** with orphan treatment annual costs range up to \$500,000 per treated patient⁴

Existing patient journey:

Current limitations and unmet clinical needs

Current patient journey



Scientific rationale:

Targeting VEGF-C/D pathway in LAM

“Lock and key” system



VEGF-C and VEGF-D are growth signals that tell lymphatic vessels to grow and become more permeable.



VEGFR-3 is the receptor on lymphatic cells that receives these signals.




When VEGF-C or VEGF-D bind to VEGFR-3, the lymphatic system gets a strong “expand and remodel” message. In LAM, this leads to abnormal, dilated, and leaky lymphatic vessels.



The problem¹

In LAM, excess VEGF-D (and VEGF-C) activates VEGFR-3 on lymphatic vessels, driving abnormal, leaky lymphatics in the lungs and accelerating disease progression.



The mechanism

By trapping VEGF-C/D with OPT-302 before they activate VEGFR-3, we aim to dampen the lymphatic signaling that fuels LAM, aiming to stabilise lung function and slow disease progression.

Why OPT-302:

A VEGF-C/D “trap” suited to LAM^{1, 2}

Fitting the Mechanism of Action with the underlying pathology

OPT-302 a VEGF-C/D “trap” designed to bind and sequester VEGF-C and VEGF-D, preventing activation of VEGFR-3-mediated lymphatic signaling



What is de-risked

- Target biology and mechanism are well characterised in lymphatic biology.
- OPT-302 has an established molecular mechanism and data informing manufacturability and safety monitoring.



What still must be proven

- Optimal route and exposure target including lung/lymphatic distribution.
- Chronic dosing safety/tolerability at LAM-relevant exposures (including immunogenicity risk management).
- Clear clinical benefit in LAM with a regulatory-aligned endpoint strategy.




Why it fits LAM

- Targets the VEGF-C/D → VEGFR-3 axis implicated in lymphatic remodeling/leakage and lymphatic manifestations in LAM.
- Intended to complement current therapy mTOR inhibition:
 - mTOR inhibitors address LAM cell growth
 - OPT-302 is positioned to address the lymphatic biology.

Delivery paths:

Evaluating optimal delivery for efficacy and safety



Regulatory strategy:

Will seek orphan designation when appropriate

Orphan drug designation may unlock

Market exclusivity

Orphan designation would grant 7-10 years of market exclusivity post-approval, across jurisdictions (US, EU, Japan & Australia) reducing competitive risk and supporting premium pricing

Regulatory incentives

Opportunity for accelerated regulator review timelines, reduced or waived filing fees, and potential tax credits to lower development costs and shorten time to market

Pricing power


Orphan drugs often command high per-patient pricing (up to \$500,000 per treated patient annually¹) due to rarity and unmet need, which can transform a small patient base into meaningful revenue.

- ✓ **Competitive protection**
- ✓ **Reduced time to market**
- ✓ **Lower development costs**
- ✓ **Premium pricing power**
- ✓ **Addressing a critical, long-neglected need in women's health**

Stage-gated plan:

Rigorous data-driven milestones and stop criteria

Pre-defined stop criteria at each gate




LAM organisations:

A family of networks and resources for individuals with LAM across the globe



Opthea will build on the substantial work completed and ongoing with the global LAM foundations, clinics and communities, establishing long-term partnerships



~70 global LAM clinics, patient data bases, biospecimen repository, focused International LAM research conference & LAMposium



...and more

Reinstatement on ASX:

Rebuilding market confidence through transparency

Opthea plans to seek reinstatement of its securities on the ASX in the first half of calendar year 2026¹

- Strategic review completed.
- In this presentation, Opthea has communicated the outcome of that strategic review and its intentions in respect of its operations and plans.
- Opthea therefore intends to re-engage with ASX with a view to making adequate market disclosure to ASX's satisfaction sufficient for ASX to permit reinstatement of Opthea's securities to quotation on ASX.



Conclusion:

Focused execution to unlock value in rare disease affecting women



Clearly defined problem in women's health with unmet need and suboptimal treatment options



OPT-302 has been through substantial clinical testing – the remaining focus is to determine its effect on a specific lung disease



Specialist LAM centres, registries and patient groups are well developed, which supports efficient studies and rapid learning from early data




Rare diseases come with market protection and attractive pricing



A convincing result could justify a family of programs in related lymphatic or VEGF-C/D-linked conditions

The family of future opportunity



Q&A

Appendix:

Full citations

- Baldwin M. *OPT-302: A novel therapy for Wet AMD*. Corporate Presentation (Opthea Limited; ASX PDF). January 2017. p. 11 (slide 11) (states “OPT-302 (soluble VEGFR-3, VEGF-C/-D ‘Trap’)”).
- Issaka, R. B., et al. (2009). Vascular Endothelial Growth Factors C and D Induce Proliferation of Lymphangiomiomatosis Cells through Autocrine Crosstalk with Endothelium. *The American Journal of Pathology*, 175(4), 1410–1420. <https://doi.org/10.2353/ajpath.2009.080830>
- Jackson TL et al. *A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration*. *Ophthalmology*. 2023 Jun; 130(6):588–597. Epub 2023 Feb 6.
- Launch Price and Access Report: Drug Approvals from 2022–2024 (Final Report). Institute for Clinical and Economic Review (ICER). Report. 2025 Oct 23. p. 11 (Table 3.2: inflation-adjusted median annual list and net launch prices for 2022–2024 approvals).
- Lynn E et al . *Am J Respir Crit Care Med*. 2024 Feb 15;209(4):456–459. doi:10.1164/rccm.202310-1736LE.
- McCormack FX et al . *Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangiomiomatosis Diagnosis and Management*. *Am J Respir Crit Care Med*. 2016 Sep 15;194(6):748–761.
- McCormack FX. et al (2011) *Efficacy and Safety of Sirolimus in Lymphangiomiomatosis*, *The New England Journal Of Medicine* Vol 364 No 17.: [Efficacy and Safety of Sirolimus in Lymphangiomiomatosis | New England Journal of Medicine](#)